• Syringin: Designing Mechanism-Ready Assays

  2026-09-02

  Syringin natural product research is strongest when chemical identity, combination pharmacology, phenotype, and pathway evidence are integrated. This guide converts RCC findings into a reproducible assay strategy while highlighting practical limitations and interpretation safeguards.

• MEHP, AhR, and Ovarian Follicle Toxicity

  2026-09-02

  Neff and colleagues show that mono(2-ethylhexyl) phthalate disrupts mouse ovarian follicle growth and estrogen-related signaling partly through aryl hydrocarbon receptor activation. Pharmacological blockade with CH 223191 reduced several MEHP-associated effects, positioning AhR signaling as a mechanistic link between phthalate exposure, altered steroidogenesis, and reproductive toxicity.

• Hexetidine (NSC-17764) in Oral Research

  2026-09-01

  Hexetidine (NSC-17764) supports reproducible planktonic, fungal, and biofilm experiments, with particular value in oral streptococcal models. Its strongest differentiation is the measurable synergy with copper ions, which enables combination screens rather than single-agent MIC testing alone.

• Biotin (Vitamin B7) for STING Assays

  2026-09-01

  Biotin (Vitamin B7) connects metabolic enzyme studies with high-sensitivity affinity workflows, but free biotin must be distinguished from activated biotinylation reagents. This guide shows how to use it in carboxylase assays, protein labeling controls, and an experimentally testable STING–DNA capture strategy inspired by shrimp antiviral research.

• L-NMMA acetate for NO Pathway Assays

  2026-08-31

  L-NMMA acetate enables controlled, pathway-level suppression of nitric oxide synthase activity in cell, biochemical, and regenerative biology workflows. Its water compatibility and broad NOS coverage make it especially useful for testing whether nitric oxide signaling drives osteogenic, inflammatory, or pharmacological phenotypes.

• Patient-Derived Gastric Cancer Assembloids

  2026-08-31

  This 2025 study introduces a patient-specific gastric cancer assembloid model that combines tumor organoids with matched stromal cell subpopulations derived from the same tumor tissue. The model reveals how stromal context alters gene expression and drug sensitivity, creating a more informative platform for resistance studies and personalized treatment research.

• EdU Cell Proliferation Kit for S-Phase Research

  2026-08-30

  The EdU Cell Proliferation Kit (TMB) is a non-radioactive 5-ethynyl-2'-deoxyuridine proliferation assay for direct S-phase DNA-synthesis measurement. Its CuAAC labeling and HRP-streptavidin/TMB detection workflow supports cell proliferation measurement, genotoxicity testing assay development, and pharmacodynamic drug evaluation.

• Azilsartan (TAK-536) in RAS Research

  2026-08-29

  Azilsartan (TAK-536) is a selective AT1 receptor inverse agonist for separating renin–angiotensin signaling from broader inflammatory effects. This guide translates its pharmacology into reproducible cardiovascular and astrocyte–microglia workflows, with practical dosing, controls, and troubleshooting strategies.

• Carfilzomib (PR-171): Translational Proteostasis

  2026-08-28

  Carfilzomib (PR-171) offers translational researchers a precise way to interrogate proteasome dependency, proteotoxic stress, and apoptosis in cancer models. This article connects its irreversible target engagement with combination strategies involving protein disulfide isomerase and histone deacetylase inhibition, while distinguishing established evidence from forward-looking experimental opportunities.

• Amplex Red for Reliable H2O2 Assays

  2026-08-28

  Amplex Red combines low-background fluorescence with flexible workflows for hydrogen peroxide detection, peroxidase measurements, and cellular ROS studies. Its greatest value emerges when mitochondrial and tissue assays include controls for carboxylesterase-driven probe conversion.

• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-08-27

  Wang et al. identify a METTL16–SENP3–LTF regulatory axis that links m6A RNA modification, SUMO-dependent protein stability, and iron handling to ferroptosis resistance in hepatocellular carcinoma. The study integrates cellular, organoid, mouse-model, biochemical, and human-sample evidence, providing a mechanistic framework for sensitizing HCC to ferroptosis-based interventions.

• Letrozole in Reliable Cell Assays

  2026-08-27

  This scenario-based guide shows how Letrozole, SKU A1307, can improve experimental consistency in cell viability, proliferation, and cytotoxicity workflows. It covers mechanism, DMSO compatibility, dose-response design, data interpretation, and practical criteria for selecting a reliable research reagent.

• Catalpol Activates Sirt6–ERα–FasL in Osteoporosis

  2026-08-26

  The reference study identifies a mechanistic link between Catalpol and osteoclast apoptosis in estrogen-deficiency osteoporosis. Using ovariectomized rats and RANKL-induced RAW 264.7 osteoclasts, the authors show that Catalpol promotes Sirt6-dependent ERα deacetylation, stabilizes ERα, and increases FasL-mediated apoptotic signaling.

• Epalrestat: From Polyol Flux to Nrf2 Assays

  2026-08-26

  Epalrestat is an aldose reductase inhibitor that connects polyol pathway inhibition with oxidative stress research. This article presents a mechanism-focused framework for selecting assays, interpreting KEAP1/Nrf2 findings, and translating evidence from diabetic neuropathy research into Parkinson’s disease models.

• α7nAChR Pyroptosis in HIV-1 BBB Breakdown

  2026-08-25

  The reference study identifies brain endothelial pyroptosis as a direct mechanism by which HIV-1 gp120 compromises blood–brain barrier integrity. It positions the α7nAChR/ROS/NF-κB/NLRP3 pathway as a targetable axis and reports that memantine and metformin can suppress this injury in experimental models.

8409 records 1/561 page Next 12345 下5页 Last page